Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease

World Journal of Gastroenterology

Volumn 15, Issue 12, 2009, Pages 1420-1426

  Actis, Giovanni C ^a   Pellicano, Rinaldo ^b   Rizzetto, Mario ^b   Ayoubi, Muhammad ^a   Leone, Nicola ^a   Tappero, Gianfranco ^a   Pazienza, Paolo ^a   Rosina, Floriano ^a  

^a GRADENIGO HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Azathioprine; Drug toxicity; Inflammatory bowel disease; Mesalamine; Remission; Thiopurines

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALLOPURINOL; AZATHIOPRINE; CYCLOSPORIN; GLITAZONE DERIVATIVE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PRESCRIPTION DRUG; PURINE DERIVATIVE; THIOL DERIVATIVE;

BRONCHIOLITIS OBLITERANS; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEVER; FLU LIKE SYNDROME; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; INFECTION; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LUNG INJURY; METHYLATION; NEPHROTOXICITY; NONHUMAN; PANCREAS INJURY; PANCREATITIS; PNEUMONIA; PRESCRIPTION; REMISSION; RESPIRATORY DISTRESS; REVIEW; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; ULCERATIVE COLITIS; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG SYNERGISM; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; PRESCRIPTION DRUGS; PURINES; SULFHYDRYL COMPOUNDS;

EID: 65549160468     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1420     Document Type: Review

References (53)

1. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459
2. Fiocchi C, Ina K, Danese S, Leite AZ, Vogel JD. Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases. Adv Exp Med Biol 2006; 579: 168-176
3. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Medica Scand 1942; 110: 577-596
4. Baron JH, Connell AM, Lennard-Jones JE, Jones FA. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 1: 1094-1096
5. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther 2007; 26: 1179-1186
6. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274: 26448-26453
7. Dallegri F, Ottonello L, Ballestrero A, Bogliolo F, Ferrando F, Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990; 31: 184-186
8. Sandoval M, Liu X, Mannick EE, Clark DA, Miller MJ. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 1997; 113: 1480-1488
9. Burress GC, Musch MW, Jurivich DA, Welk J, Chang EB. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997; 113: 1474-1479
10. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837-844
11. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81: 444-449
12. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-266
13. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 1574-1581
14. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-1197
15. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; CD000544
16. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539
17. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis 2003; 9: 308-315
18. Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology. Minerva Gastroenterol Dietol 2008; 54: 239-242
19. Elion GB, Callahan S, Rundles RW, Hitchings GH. Relationship between metabolic fates and antitumor activities of thiopurines. Cancer Res 1963; 23: 1207-1217
20. Autobiography of Gertrude B. Elion, the Nobel Prize in Physiology or Medicine 1988. Oncologist 2006; 11: 966-968
21. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962; 49(2): 592-593
22. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-767
23. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987
24. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-219
25. Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-1818
26. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-85
27. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-22
28. Ardizzone S, Cassinotti A, Actis GC, Duca P, D'Albasio G, Gai E, Massari A, Bosani M, Colombo E, Manes G, Maconi G, Bianchi-Porro G. Maintenance treatment with azathioprine in ulcerative colitis:outcomes after drug withdrawal in patients with sustained remission. Gastroenterology 2007; 132(4): S1138
29. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007; 7: 13
30. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005; 22: 1-16
31. Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; Epub ahead of print
32. Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-782
33. Actis GC, Marzano A, Pellicano R, Rizzetto M. How important is mesalamine in the maintenance of steroid-refractory colitis? Inflamm Bowel Dis 2008; 14: 1026
34. Stocco G, Martelossi S, Malusa' N, Marino S, Decorti G, Bartoli F, Ventura A. Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse. Dig Dis Sci 2008; 53: 3246-3249
35. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-475
36. de Boer NK, Wong DR, Jharap B, de Graaf P, Hooymans PM, Mulder CJ, Rijmen F, Engels LG, van Bodegraven AA. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102: 2747-2753
37. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-670
38. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12: 251-257
39. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85
40. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 1122-1128
41. Shah JA, Edwards CM, Probert CS. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur J Gastroenterol Hepatol 2008; 20: 169-173
42. Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther 2009; 29: 459-469
43. Bernstein CN. Cancer prevention strategies in inflammatory bowel disease. In: Bayless T, Hanauer SB, editors. Advanced therapy of inflammatory bowel disease. London: BC Decker Inc, 2001: 257-261
44. Actis GC, Pazienza P, Rosina F. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm Allergy Drug Targets 2008; 7: 1-5
45. Thompson EA. PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol Cells 2007; 24: 167-176
46. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341-1349
47. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998; 92: 3569-3577
48. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH Jr. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 527-535
49. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145
50. Ben-Horin S, Goldstein I, Fudim E, Picard O, Yerushalmi Z, Barshack I, Bank I, Goldschmid Y, Meir SB, Mayer L, Chowers Y. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 2009; 58: 396-403
51. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 2008; 27 Suppl 1: 15-21
52. Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol 2008; 14: 5512-5518
53. Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008; 10: 585-590